Board of Advisors
Richard Zhao has 20 years of experience in M&A, Business Development and Sales & Marketing Management on both global and regional levels. Prior to Tasly International Capital, Mr. Zhao was Chief Investment Officer and SVP, Medical Technology Division of Fosun Pharma. Prior to joining Fosun Pharma, Mr. Zhao held various executive positions at Bayer Healthcare and Philips Healthcare, driving international business growth and expansion. He was one of the early explorers in the 1990’s to introduce multinational companies to China, and has helped many multinational companies enter and operate in China through Shanghai Free Trade Zone.
Mr. Zhao holds an MBA degree from CEIBS and received executive education (CPD) from the Wharton School of University of Pennsylvania.
Tasly Capital is an investment arm of Tasly Holding Group. Tasly is a leading Chinese pharmaceutical company based in the city of Tianjin. It was established in 1994 and is notably producing traditional Chinese medicines. It has a turnover of 4 billion US dollars, 10,000 employees and is listed on the Shanghai Stock Exchange.